comparemela.com

Latest Breaking News On - Orbimed israel - Page 1 : comparemela.com

Chemomab Therapeutics : Notice and Proxy Statement with respect to the Company s annual general meeting of the shareholders (the Meeting ) to be held on June 10, 2024, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting - Form 6-K

May 3, 2024 Dear Chemomab Therapeutics Ltd. Shareholders: We cordially.

Tel avivNorth carolinaUnited statesHa afonWashington universityRamat ganDuke universityPeter thielSomekh chaikinBalan mosesClaude nicaiseHerzliya pituachNeil cohenChristian angermayerKiryat atidimSigal fattal

Chemomab Therapeutics : Notice and Proxy Statement with respect to the Company s annual general meeting of the shareholders (the Meeting ) to be held on August 7, 2023, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting

July 3, 2023 Dear Chemomab Therapeutics Ltd. Shareholders: We cordially.

Bruxelles capitaleTel avivIsrael generalRamat ganUnited statesSaint luciaCity ofUnited kingdomNissim darvishClaude nicaiseBalan mosesSigal fattalJill quigleyWadi morPeter thielMatthew frankel

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

─Adi Mor, PhD, Co-founder, Board Director and Chief Scientific Officer, Reappointed to CEO Role─ ─Sigal Fattal, Vice President Finance, Reappointed as. | June 5, 2023

Wadi morSigal fattalNissim darvishBarbara lindheimDonald marvinDale pfostIrina kofflerTel aviv universityStrategic communicationsPrnewswire chemomab therapeutics ltdUs national institutes of healthChemomab therapeutics ltdLifesci advisorsBoard directorChief scientific officerVice president finance

BenevolentAI : 9xchange joins forces with BenevolentAI to integrate its AI technology into its innovative biopharma marketplace

Marketplace and partnership promote information sharing and collaboration across the biopharma industry to accelerate new drug discovery and development. . | May 16, 2023

Tel avivNew yorkUnited statesCity ofUnited kingdomMatt fujisawaRajin kangCompany euronext amsterdamVp communicationsEuronext amsterdamFounder anat naschitzOrbimed israelBenevolent platformBenevolentai stock exchangePress releaseNd bai lu2355630455

9xchange joins forces with BenevolentAI to integrate its AI technology into its innovative biopharma marketplace

9xchange, a biopharma marketplace created for innovators to match, buy and sell drug assets, today announces it has partnered with BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading AI-enabled drug discovery and development company. The partnership aims to leverage BenevolentAI's .

Tel avivMatt fujisawaCompany euronext amsterdamEuronext amsterdamFounder anat naschitzOrbimed israel

vimarsana © 2020. All Rights Reserved.